An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face

Galderma

Status and phase

Completed

Phase 4

Conditions

Aged Skin

Treatments

Device: Restylane Vital Skinboosters Lidocaine

Study type

Interventional

Funder types

Industry

Identifiers

NCT02403986

CTN 05DF1404

Details and patient eligibility

About

A randomised, multi-centre, parallel-group efficacy and safety study evaluating two and three initial treatment sessions of Restylane Skinboosters Vital Lidocaine in the face.

Full description

Approximately 50 female subjects shall be treated with two or three initial treatment sessions including long-term follow-up 18 months after the initial treatment regimen. Efficacy and safety to be evaluated.

Enrollment

53 patients

Sex

Female

Ages

35 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of signed and dated informed consent to participate in the study.
Non-pregnant, non-breast feeding female aged 35-45 years.
Visible signs of aging in the face
Intent to improve skin hydration, skin structure and the elasticity of the skin using - Restylane Skinboosters Vital Lidocaine.

Exclusion criteria

Extensively photo damaged and aged skin.
Woman who plan to become pregnant during the course of the study.
Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel.
Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics.
History of severe or multiple allergies manifested by anaphylaxis.
History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation, Omega-3 or Vitamin E within 10 days before study treatment
Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids (inhaled corticoids are allowed) within three months before study treatment.
Previous tissue augmenting therapy or contouring with permanent filler or fat-injection in the face.
Previous tissue augmenting therapy, contouring or revitalisation treatment with non-permanent filler, neurotoxin or revitalisation preparations (e.g. Hyal System or Restylane Skinboosters) in the face within 12 months before study treatment.
Previous tissue revitalisation treatment with laser or light, radiofrequency, focused ultrasound, chemical peeling, dermabrasion, mesotherapy or any other similar treatment with influence on skin quality in the face within 6 months before study treatment.
Previous aesthetic facial surgical therapy, liposuction or tattoo in the face.
Previous sinus surgery or dental root surgery within 3 months before study treatment.
Active skin disease, inflammation or related conditions, such as infection, perioral dermatitis, seborrheic eczema, rosacea, acne, psoriasis or herpes zoster in the face.
History of or active collagen diseases or autoimmune diseases such as systemic lupus erythematosus, rheumatic arthritis, skin or systemic sclerosis.
Tendency to form keloids, hypertrophic scars or any other healing disorder.
History of radiation of or cancerous or pre-cancerous lesions (e.g. actinic keratosis) in the face.
Use of systemic or facial topical retinoic acid within 12 months before study treatment.
Nicotine use within 6 months before study treatment. (Occasional smoking, such as 1-5 cigarettes per week, or similar amount of nicotine, is allowed).
Any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion (e.g. chronic, relapsing or hereditary disease that may interfere with the outcome of the study.
Other condition preventing the subject from entering the study in the Investigator's opinion, e.g. subjects not likely to avoid other facial aesthetic treatments, subjects anticipated to be unreliable, unavailable or incapable of understanding the study assessments or having unrealistic expectations of the treatment result.
Study site personnel or close relatives of the study site personnel (e.g. parents, children, siblings and spouse) or employees at the Sponsor company.
Participation in any other clinical study within 3 months before study treatment.